Manufacturing Part Of GSK Proposal For Single Dose Antimalarial In India
GlaxoSmithKline has proposed to market and manufacture antimalarial Krintafel in India and an expert panel has sought additional information to progress a review of these plans. GSK and partner MMV aim to ensure that the cost of the therapy does not impede access.
You may also be interested in...
The latest drug development news and highlights from our US FDA Performance Tracker.
Approval could bring GlaxoSmithKline a tropical disease priority review voucher.
Syngene’s COO, Mahesh Bhalgat, tells Scrip the firm is better placed than some peers to serve clients for biologics-based advanced therapies and address the cost element for new modalities like mRNA. He also outlines the research, development and manufacturing services company's capabilities in oligonucleotide-based therapeutics, an area that's seeing growing interest.